Target Identification & Indication Selection
Pick the right shots on goal. We combine biology, epidemiology, standard‑of‑care gaps, and feasibility to prioritize indications and targets you can credibly prosecute.
What you get
Indication landscape scan (epidemiology, standard of care, unmet need)
Target/biology fit to mechanism & modality
Feasibility filters (delivery, biomarkers, patient access, endpoints)
Competitive snapshot (differentiation, crowding, partner activity)
Scoring model & short list (3–5 priority indications/targets)
Evidence plan to validate top choices
Our process
Objectives & constraints — success criteria, timelines, capabilities.
Data aggregation — literature, public datasets, registries, KOL input.
Scoring & short list — weighted criteria (unmet need, translatability, feasibility, competition).
Validation — targeted KOL calls, sensitivity checks.
Recommendation — go/no‑go logic, next experiments, partnering angles.
Indication/target scorecards (top 3–5)
Prioritization matrix (weights & rationale)
Rationale deck with risks & mitigations
Evidence plan (assays, in vivo/in vitro, biomarkers)
Slides for internal/investor discussions
Deliverables
Do you run discovery experiments?
No wet‑lab work. We design the evidence plan and, if needed, refer to CROs or advisors.
Can you provide validation from KOLs?
Yes—select expert calls for validation, subject to availability and conflicts (additional fee).
Do you propose endpoints/biomarkers?
We recommend feasible early endpoints and biomarker strategies aligned to SoC and modality.